StockMacro
Company, fund or insider

Help

Menu

Champions Oncology

$4.34 -27% in 6 monthsMarket cap $60.4M

CSBR on XNAS, Health Care, Champions Oncology, Inc., job postings

Measures activity, not value. Not investment advice.

Revenue rose 8.8% in the latest quarter but the stock is down 35% in a year.

  • BadFree cash flow was -$6.1M over 12 months, with cash at $4.4M

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 31 Jul 2026

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
214
Website
championsoncology.com
Listed
Nasdaq, US
Last results
10 Sep 2026
Next results
expected around 14 Dec 2026 (an estimate: a year ago it reported on 15 Dec 2025)
Revenue and net income per quarter. Quarter to 31 Jul 2026: revenue $15.2M, net loss $426K.
Quarter to 31 Jan 2022: revenue $13.2M, net income $787KQuarter to 31 Jan 2022: revenue $13.2M, net income $787KQuarter to 30 Apr 2022: revenue $12.9M, net income -$344KQuarter to 30 Apr 2022: revenue $12.9M, net income -$344KQuarter to 31 Jul 2022: revenue $13.7M, net income -$319KQuarter to 31 Jul 2022: revenue $13.7M, net income -$319KQuarter to 31 Oct 2022: revenue $14.3M, net income -$16KQuarter to 31 Oct 2022: revenue $14.3M, net income -$16KQuarter to 31 Jan 2023: revenue $12.8M, net income -$2.4MQuarter to 31 Jan 2023: revenue $12.8M, net income -$2.4MQuarter to 30 Apr 2023: revenue $13.1M, net income -$2.6MQuarter to 30 Apr 2023: revenue $13.1M, net income -$2.6MQuarter to 31 Jul 2023: revenue $12.6M, net income -$2.6MQuarter to 31 Jul 2023: revenue $12.6M, net income -$2.6MQuarter to 31 Oct 2023: revenue $11.6M, net income -$2.1MQuarter to 31 Oct 2023: revenue $11.6M, net income -$2.1MQuarter to 31 Jan 2024: revenue $12.0M, net income -$2.5MQuarter to 31 Jan 2024: revenue $12.0M, net income -$2.5MQuarter to 30 Apr 2024: revenue $14.0M, net income -$109KQuarter to 30 Apr 2024: revenue $14.0M, net income -$109KQuarter to 31 Jul 2024: revenue $14.1M, net income $1.3MQuarter to 31 Jul 2024: revenue $14.1M, net income $1.3MQuarter to 31 Oct 2024: revenue $13.5M, net income $728KQuarter to 31 Oct 2024: revenue $13.5M, net income $728KQuarter to 31 Jan 2025: revenue $17.0M, net income $4.5MQuarter to 31 Jan 2025: revenue $17.0M, net income $4.5MQuarter to 30 Apr 2025: revenue $12.4M, net income -$1.8MQuarter to 30 Apr 2025: revenue $12.4M, net income -$1.8MQuarter to 31 Jul 2025: revenue $14.0M, net income -$436KQuarter to 31 Jul 2025: revenue $14.0M, net income -$436KQuarter to 31 Oct 2025: revenue $15.0M, net income $268KQuarter to 31 Oct 2025: revenue $15.0M, net income $268KQuarter to 31 Jan 2026: revenue $16.6M, net income -$279KQuarter to 31 Jan 2026: revenue $16.6M, net income -$279KQuarter to 30 Apr 2026: revenue $13.8M, net income -$667KQuarter to 30 Apr 2026: revenue $13.8M, net income -$667KQuarter to 31 Jul 2026: revenue $15.2M, net income -$426KQuarter to 31 Jul 2026: revenue $15.2M, net income -$426K
31 Jan 2022RevenueNet incomeNet losstallest bar $17.0M31 Jul 2026
See the numbers
Quarter toRevenueNet income
31 Jul 2026$15.2M-$426K
30 Apr 2026$13.8M-$667K
31 Jan 2026$16.6M-$279K
31 Oct 2025$15.0M$268K
31 Jul 2025$14.0M-$436K
30 Apr 2025$12.4M-$1.8M
31 Jan 2025$17.0M$4.5M
31 Oct 2024$13.5M$728K
31 Jul 2024$14.1M$1.3M
30 Apr 2024$14.0M-$109K
31 Jan 2024$12.0M-$2.5M
31 Oct 2023$11.6M-$2.1M
31 Jul 2023$12.6M-$2.6M
30 Apr 2023$13.1M-$2.6M
31 Jan 2023$12.8M-$2.4M
31 Oct 2022$14.3M-$16K
31 Jul 2022$13.7M-$319K
30 Apr 2022$12.9M-$344K
31 Jan 2022$13.2M$787K
Fundamentals, 12 months to 31 Jul 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $60.7M $56.9M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +6.7% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$1.1M $2.9M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 49.8% 48.5% 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -1.7% 4.7% -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -1.8% 5.1% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -29.8% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$6.1M $7.2M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $4.4M $10.3M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$4.4M (net cash) -$10.3M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.28
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 1.00 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 0.92 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 15.5 2.0

Latest = 12 months to 31 Jul 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Champions OncologyCSBR (this company) $60.4Mloss1.00+6.7%-1.8%
Neumora TherapeuticsNMRA $63.0Mloss–––
Coherus OncologyCHRS $57.1Mloss1.1-36%-253%
Atara BiotherapeuticsATRA $64.5Mloss16.3-97%-369%
Tenaya TherapeuticsTNYA $65.3Mloss–––
Cognition TherapeuticsCGTX $55.4Mloss–––

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+8.8%

$15.2M vs $14.0M (quarter ended 31 Jul 2026)

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-7.1%

26 13F filers vs 28

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

42%

5.8M shares held by 13F filers (30 Sep 2026) of 13.9M outstanding (9 Sep 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

0.5%

72K shares sold short (30 Oct 2026) of 13.9M outstanding (9 Sep 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

8.6

72K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-6.9%

78K shares sold short in the report before, 72K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

34%

34% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 35%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

4

4 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

4 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $4.34 on 20 Nov 2026, -35% over 12 months (12-month range $4.34 to $7.80)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $0).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 2 published in the last 12 months, -50% on the 12 months before.
Revenue per quarter. Revenue $15.2M in the latest quarter, +8.8% on a year earlier.
Capital spending per quarter. Capital spending $55K in the latest quarter, +20% on a year earlier.
Institutional holders (13F filers). 26 13F filers reported holding it in the latest 13F quarter, -3.7% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
30 Mar 20268-K and other filingsDirector or officer change
30 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Mar 2025Sharp changeQuarterly revenue change: quarterly revenue change, 17.0M vs usual 12.9M (2025-01-31); 1.4x the same period a year earlier
3 Oct 20248-K and other filingsDirector or officer change
3 Oct 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Oct 20238-K and other filingsDirector or officer change
17 Oct 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Mar 2023: $50K published
Month from 1 Sep 2023: $125K published
Month from 1 Oct 2023: $174K published
Month from 1 Dec 2023: $46K published
Month from 1 Jan 2024: $96K published
H-1B/E-3 applications certified
Quarter from 1 Jul 2023: 1 published
Quarter from 1 Oct 2023: 1 published
Quarter from 1 Oct 2024: 1 published
Quarter from 1 Apr 2025: 2 published
Quarter from 1 Jul 2025: 1 published
Quarter from 1 Oct 2025: 1 published
Quarter from 1 Jul 2026: 1 published
Quarter from 1 Oct 2026: 1 published
Revenue per quarter
Quarter ended 31 Oct 2021: $11.8M, +16% on a year earlier; public on 14 Dec 2021
Quarter ended 31 Jan 2022: $13.2M, +22% on a year earlier; public on 16 Mar 2022
Quarter ended 30 Apr 2022: $12.9M, +22% on a year earlier; public on 23 Jul 2022
Quarter ended 31 Jul 2022: $13.7M, +22% on a year earlier; public on 13 Sep 2022
Quarter ended 31 Oct 2022: $14.3M, +21% on a year earlier; public on 14 Dec 2022
Quarter ended 31 Jan 2023: $12.8M, -3.2% on a year earlier; public on 17 Mar 2023
Quarter ended 30 Apr 2023: $13.1M, +1.5% on a year earlier; public on 25 Jul 2023
Quarter ended 31 Jul 2023: $12.6M, -8.6% on a year earlier; public on 14 Sep 2023
Quarter ended 31 Oct 2023: $11.6M, -19% on a year earlier; public on 14 Dec 2023
Quarter ended 31 Jan 2024: $12.0M, -5.9% on a year earlier; public on 16 Mar 2024
Quarter ended 30 Apr 2024: $14.0M, +7.1% on a year earlier; public on 20 Jul 2024
Quarter ended 31 Jul 2024: $14.1M, +12% on a year earlier; public on 14 Sep 2024
Quarter ended 31 Oct 2024: $13.5M, +17% on a year earlier; public on 17 Dec 2024
Quarter ended 31 Jan 2025: $17.0M, +42% on a year earlier; public on 18 Mar 2025
Quarter ended 30 Apr 2025: $12.4M, -12% on a year earlier; public on 24 Jul 2025
Quarter ended 31 Jul 2025: $14.0M, -0.5% on a year earlier; public on 16 Sep 2025
Quarter ended 31 Oct 2025: $15.0M, +11% on a year earlier; public on 16 Dec 2025
Quarter ended 31 Jan 2026: $16.6M, -2.8% on a year earlier; public on 13 Mar 2026
Quarter ended 30 Apr 2026: $13.8M, +12% on a year earlier; public on 28 Jul 2026
Quarter ended 31 Jul 2026: $15.2M, +8.8% on a year earlier; public on 12 Sep 2026
Capital spending per quarter
Quarter ended 31 Oct 2021: $566K, +12% on a year earlier; public on 14 Dec 2021
Quarter ended 31 Jan 2022: $405K, -66% on a year earlier; public on 16 Mar 2022
Quarter ended 30 Apr 2022: $506K, -41% on a year earlier; public on 23 Jul 2022
Quarter ended 31 Jul 2022: $754K, -17% on a year earlier; public on 13 Sep 2022
Quarter ended 31 Oct 2022: $604K, +6.7% on a year earlier; public on 14 Dec 2022
Quarter ended 31 Jan 2023: $754K, +86% on a year earlier; public on 17 Mar 2023
Quarter ended 30 Apr 2023: $760K, +50% on a year earlier; public on 25 Jul 2023
Quarter ended 31 Jul 2023: $668K, -11% on a year earlier; public on 14 Sep 2023
Quarter ended 31 Oct 2023: $153K, -75% on a year earlier; public on 14 Dec 2023
Quarter ended 31 Jan 2024: $126K, -83% on a year earlier; public on 16 Mar 2024
Quarter ended 31 Jul 2024: $0, -100% on a year earlier; public on 14 Sep 2024
Quarter ended 30 Apr 2025: $253K; public on 24 Jul 2025
Quarter ended 31 Jul 2025: $46K; public on 16 Sep 2025
Quarter ended 31 Oct 2025: $242K; public on 16 Dec 2025
Quarter ended 31 Jan 2026: $37K; public on 13 Mar 2026
Quarter ended 30 Apr 2026: $239K, -5.5% on a year earlier; public on 28 Jul 2026
Quarter ended 31 Jul 2026: $55K, +20% on a year earlier; public on 12 Sep 2026
Institutional holders (13F filers)
31 Dec 2021 report: 31; public on 14 Feb 2022
31 Mar 2022 report: 30; public on 16 May 2022
30 Jun 2022 report: 32; public on 15 Aug 2022
30 Sep 2022 report: 30; public on 14 Nov 2022
31 Dec 2022 report: 29; public on 14 Feb 2023
31 Mar 2023 report: 29; public on 15 May 2023
30 Jun 2023 report: 27; public on 14 Aug 2023
30 Sep 2023 report: 28; public on 14 Nov 2023
31 Dec 2023 report: 23; public on 14 Feb 2024
31 Mar 2024 report: 25; public on 15 May 2024
30 Jun 2024 report: 23; public on 14 Aug 2024
30 Sep 2024 report: 22; public on 14 Nov 2024
31 Dec 2024 report: 24; public on 14 Feb 2025
31 Mar 2025 report: 33; public on 15 May 2025
30 Jun 2025 report: 30; public on 14 Aug 2025
30 Sep 2025 report: 27; public on 14 Nov 2025
31 Dec 2025 report: 27; public on 17 Feb 2026
31 Mar 2026 report: 24; public on 15 May 2026
30 Jun 2026 report: 28; public on 14 Aug 2026
30 Sep 2026 report: 26; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, quarter at $15.2M (31 Jul 2026), 1.1× its normal quarter; higher than 97% of its own history.
  • Insider net buying (open market): Insiders bought a net $0 in the last 12 months (the 12 months before: $0).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 2 published in the last 12 months, -50% on the 12 months before.
  • Revenue per quarter: Revenue $15.2M in the latest quarter, +8.8% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 49 insider trades

No trades in the last 90 days; the latest was filed 16 Jan 2024. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
16 Jan 2024Daniel Newman MendelsonDirectorBuy1,000$6.50$6KForm 4
12 Jan 2024Daniel Newman MendelsonDirectorBuy2,000$6.27$13KForm 4
11 Jan 2024Daniel Newman MendelsonDirectorBuy2,944$6.31$19KForm 4
10 Jan 2024Daniel Newman MendelsonDirectorBuy3,000$6.25$19KForm 4
9 Jan 2024Daniel Newman MendelsonDirectorBuy1,000$6.15$6KForm 4
8 Jan 2024Daniel Newman MendelsonDirectorBuy2,000$6.09$12KForm 4
8 Jan 2024Daniel Newman MendelsonDirectorBuy3,000$6.12$18KForm 4
4 Jan 2024Daniel Newman MendelsonDirectorBuy500$5.83$3KForm 4

26 institutions reported shares at the end of Q3 2026, 42% of the shares outstanding; 1 opened a position, 3 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Battery Management Corp.2.4M17.4%$12.1MNo change
NEA Management Company, LLC1.7M12.3%$8.6MNo change
Vanguard Capital Management LLC301K2.17%$1.5MNo change
Tocqueville Asset Management L.P.296K2.12%$1.5MNo change
Bank of America Corp213K1.53%$1.1M-1,390-0.6%
Morgan Stanley196K1.41%$978K-40K-17%
Renaissance Technologies LLC130K0.93%$648K-9,400-6.8%
BlackRock, Inc.129K0.92%$643K-1,309-1.0%
Mink Brook Asset Management LLC111K0.80%$557KNo change
Geode Capital Management, LLC76K0.55%$382KNo change

Federal contracts

All 1 federal contracts

No new award in 12 months; the latest was signed 18 Sep 2017. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
18 Sep 2017Department of Health and Human ServicesNational Institutes of Health$2.0MIGF::OT::IGF (CHAMPIONS ONCOLOGY) (SBIR TOPIC 355) (DIRECT TO PHASE II) TO ADDRESS THE SLOW GROWTH RATE OF PROSTATE PDXS BY ELIMINATING LOGISTICAL BARRIERS THROUGH DEVELOPMENT OF CDX (I.E., PDX FROM CIRCULATING TUMOR CELLS) MODELS. PERIOD OF PERFORMANCE: 09/19/2017 - 09/18/2019USAspending

Company events

All 14 company events

In 12 months: 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
30 Mar 2026Director or officer change8-K
3 Oct 2024Director or officer change8-K
17 Oct 2023Director or officer change8-K
12 Feb 2021Director or officer change8-K
28 Apr 2017Delisting notice or listing transfer8-K
26 Jan 2017Director or officer change8-K
29 Nov 2016Director or officer change8-K
1 Nov 2016Director or officer change8-K

The 5 newest of 34 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 30 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 30 Mar 2026Filings record

    Director or officer change

  3. 18 Mar 2025Financials change

    reported revenue of $17.0M for the quarter ended 31 Jan 2025, 1.4× the same quarter last year.

    Same quarter last year: $12.0M; its normal quarter is $12.9M.

    See the evidence
    This period
    $17.0M (the quarter ended 31 Jan 2025)
    Normal quarter (median of 8 earlier)
    $12.9M
    Typical spread (median absolute deviation)
    $735K
    How far from its usual level
    +3.2
    Same quarter last year
    $12.0M
    History used
    5,298 days
    2023-01-31: $12.8M2023-04-30: $13.1M2023-07-31: $12.6M2023-10-31: $11.6M2024-01-31: $12.0M2024-04-30: $14.0M2024-07-31: $14.1M2024-10-31: $13.5M2025-01-31: $17.0M
    the quarter ended 31 Jan 20258 earlier quartersnormal: $12.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  4. 3 Oct 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 3 Oct 2024Filings record

    Director or officer change

  6. 17 Jan 2024Insiders record

    Mendelson Daniel Newman (director) bought 1,000 shares of CSBR ($6,500) (dated 16 Jan 2024)

  7. 13 Jan 2024Insiders record

    Mendelson Daniel Newman (director) bought 2,000 shares of CSBR ($12,540) (dated 12 Jan 2024)

  8. 12 Jan 2024Insiders record

    Mendelson Daniel Newman (director) bought 2,944 shares of CSBR ($18,577) (dated 11 Jan 2024)

  9. 11 Jan 2024Insiders record

    Mendelson Daniel Newman (director) bought 3,000 shares of CSBR ($18,750) (dated 10 Jan 2024)

  10. 10 Jan 2024Insiders record

    Mendelson Daniel Newman (director) bought 1,000 shares of CSBR ($6,150) (dated 9 Jan 2024)

  11. 9 Jan 2024Insiders record

    Mendelson Daniel Newman (director) bought 2,000 shares of CSBR ($12,180) (dated 8 Jan 2024)

  12. 9 Jan 2024Insiders record

    Mendelson Daniel Newman (director) bought 3,000 shares of CSBR ($18,360) (dated 8 Jan 2024)

  13. 5 Jan 2024Insiders record

    Mendelson Daniel Newman (director) bought 500 shares of CSBR ($2,915) (dated 4 Jan 2024)

  14. 27 Dec 2023Insiders record

    Mendelson Daniel Newman (director) bought 2,500 shares of CSBR ($12,300) (dated 26 Dec 2023)

  15. 22 Dec 2023Insiders record

    Mendelson Daniel Newman (director) bought 2,100 shares of CSBR ($10,122) (dated 21 Dec 2023)

  16. 21 Dec 2023Insiders record

    Mendelson Daniel Newman (director) bought 5,000 shares of CSBR ($23,750) (dated 20 Dec 2023)

  17. 17 Oct 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  18. 17 Oct 2023Filings record

    Director or officer change

  19. 17 Oct 2023Insiders record

    Mendelson Daniel Newman (director) bought 4,000 shares of CSBR ($24,640) (dated 16 Oct 2023)

  20. 17 Oct 2023Insiders record

    Mendelson Daniel Newman (director) bought 5,000 shares of CSBR ($31,100) (dated 16 Oct 2023)

  21. 17 Oct 2023Insiders record

    Mendelson Daniel Newman (director) bought 1,500 shares of CSBR ($8,925) (dated 16 Oct 2023)

  22. 14 Oct 2023Insiders record

    Mendelson Daniel Newman (director) bought 5,000 shares of CSBR ($32,000) (dated 13 Oct 2023)

  23. 12 Oct 2023Insiders record

    Mendelson Daniel Newman (director) bought 1,100 shares of CSBR ($7,051) (dated 11 Oct 2023)

  24. 11 Oct 2023Insiders record

    Mendelson Daniel Newman (director) bought 1,530 shares of CSBR ($9,914) (dated 10 Oct 2023)

  25. 7 Oct 2023Insiders record

    Mendelson Daniel Newman (director) bought 2,000 shares of CSBR ($12,940) (dated 6 Oct 2023)

  26. 5 Oct 2023Insiders record

    Mendelson Daniel Newman (director) bought 5,000 shares of CSBR ($32,000) (dated 4 Oct 2023)

  27. 5 Oct 2023Insiders record

    Mendelson Daniel Newman (director) bought 2,500 shares of CSBR ($15,750) (dated 4 Oct 2023)

  28. 28 Sep 2023Insiders record

    Mendelson Daniel Newman (director) bought 5,000 shares of CSBR ($28,250) (dated 27 Sep 2023)

  29. 26 Sep 2023Insiders record

    Mendelson Daniel Newman (director) bought 5,000 shares of CSBR ($26,400) (dated 25 Sep 2023)

  30. 26 Sep 2023Insiders record

    Mendelson Daniel Newman (director) bought 3,812 shares of CSBR ($20,966) (dated 25 Sep 2023)

  31. 26 Sep 2023Insiders record

    Mendelson Daniel Newman (director) bought 4,018 shares of CSBR ($22,139) (dated 25 Sep 2023)

  32. 26 Sep 2023Insiders record

    Mendelson Daniel Newman (director) bought 5,000 shares of CSBR ($27,550) (dated 25 Sep 2023)

  33. 22 Mar 2023Insiders record

    Morris Ronnie (CEO) bought 12,382 shares of CSBR ($50,023) (dated 21 Mar 2023)

  34. 12 Feb 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 12 Feb 2021Filings record

    Director or officer change

  36. 31 Mar 2020Insiders record

    Mendelson Daniel Newman (director) bought 1,220 shares of CSBR ($7,213) (dated 30 Mar 2020)

  37. 27 Mar 2020Insiders record

    Mendelson Daniel Newman (director) bought 26 shares of CSBR ($143) (dated 26 Mar 2020)

  38. 25 Mar 2020Insiders record

    Morris Ronnie (CEO) bought 75 shares of CSBR ($356) (dated 24 Mar 2020)

  39. 21 Dec 2018Insiders record

    Morris Ronnie (CEO) bought 20,000 shares of CSBR ($148,800) (dated 20 Dec 2018)

  40. 14 Nov 2018Institutional holdings change

    saw 21 13F filers open a new position in the quarter ended 30 Sep 2018, 7.0× the same quarter last year.

    Same quarter last year: 3; its normal quarter is 3.

    See the evidence
    This period
    21 (the quarter ended 30 Sep 2018)
    Normal quarter (median of 8 earlier)
    3
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +4.9
    Same quarter last year
    3
    History used
    1,826 days
    2016-09-30: 62016-12-31: 02017-03-31: 72017-06-30: 12017-09-30: 32017-12-31: 22018-03-31: 32018-06-30: 72018-09-30: 21
    the quarter ended 30 Sep 20188 earlier quartersnormal: 3

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

Showing the newest 40 of 63 entries; narrow the window or the kind of data to see older ones.

Not listed: 96 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000771856
Ticker
CSBR
Domain
championsoncology.com
Employer name
Champions Oncology, Inc (1 unverified)
Hq location
MD|BALTIMORE|21205 (1 unverified)
Name
CHAMPIONS BIOTECHNOLOGY, INC., Champions Oncology, Inc., CHAMPIONS SPORTS INC
Uei
K7EZES58U9N8
Wikidata
Q16829203
Wikipedia
Champions Oncology
  • DOL H-1B labor condition applications and PERM certifications70 data points24 Feb 2020 to 6 Jul 2026
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)103 records15 Mar 2016 to 11 Sep 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1035 data points30 Apr 2010 to 9 Sep 2026
  • SEC Form 4 insider transactions49 records, 152 data points21 Sep 2016 to 16 Jan 2024
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4084 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 12 data points15 Apr 2015 to 1 Apr 2020
  • Wikipedia pageviews2881 data points1 Jan 2019 to 21 Nov 2026